Inducible overexpression of VEGF-D in obesity expands adipose lymphatics. A: RNA expression for the lymphangiogenic VEGFR-3 ligands Vegf-c and Vegf-d is physiologically elevated in high-fat diet (HFD)--fed obese mouse inguinal adipose tissue compared with chow-fed mice. B: Induction of VEGF-D translation in Adipo-VD mice elevates Vegf-d and lymphatic endothelial cell marker RNAs in inguinal white adipose tissue. C: Brown adipose tissue exhibits higher VEGF-D RNA induction in Adipo-VD mice. D: Immunofluorescence of lymphatic (green; LYVE-1) and blood (red; endomucin) endothelium in inguinal white adipose tissue. E: Quantitation of LYVE-1e and endomucin-positive pixels on inguinal adipose tissue section images. F: Immunofluorescence of lymphatic (green; LYVE-1) and blood (red; endomucin) endothelium in interscapular brown adipose tissue. G: Quantitation of LYVE-1-- and endomucin-positive pixels on brown adipose tissue section images. H: Podoplanin (green) and Prox-1 (red) labeling of lymphatic structures in brown adipose tissue. I: VEGFR-3 (green) labeling of lymphatic structures in white adipose tissue. Blue shows DAPI in all images. J: Whole-mount LYVE-1 immunofluorescence in inguinal white adipose tissue demonstrates LYVE-1+ cells resident in adipose tissue. In Adipo-VD tissue, lymphatic structures form between and around adipocytes. n = 4 (A); n = 8 (B and D--G). *P < 0.05 versus _rtTA. Scale bars: 100 μm (D, F, I, and J); 50 μm (H). Credit: American Journal of Pathology

The search by scientists to find ways to combat obesity continues. Recently, investigators have been exploring whether they can engage the lymphatic system to help regulate obesity-induced inflammation of fat (adipose) tissue and restore systemic metabolic fitness. In a study appearing in he American Journal of Pathology, researchers report that augmenting lymphatic vessel formation in obese adipose tissue via vascular endothelial growth factor (VEGF-D) signaling reduced obesity-associated immune accumulation and improved metabolic responsiveness, suggesting a new approach to ameliorating some obesity-associated metabolic abnormalities.

In obesity, tissue expands and becomes dysfunctional, leading to the appearance of a cluster of medical issues known as "the metabolic syndrome," which includes increased , high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels. The adipose tissue found in obesity exhibits symptoms of chronic inflammation, including hypoxia, immune cell accumulation, and fibrosis, leading to spilling over of pro-inflammatory substances and excess lipids into the circulation. This allows fat to circulate and be deposited in other tissues that are less well-equipped to safely store it.

"Adipose tissue inflammation is at the root of the epidemic of obesity's metabolic syndrome. Reducing inflammation in mice has worked to improve metabolism but has not translated well to humans," explained lead investigator Joseph M. Rutkowski, Ph.D., of the Division of Lymphatic Biology, Department of Medical Physiology, at Texas A&M College of Medicine, College Station, TX, USA. "Understanding the mechanisms of adipose inflammation and how to regulate it sheds light on the biology of our current obesity problem. We hypothesized that increasing lymphangiogenesis (formation of ) in adipose tissue would help to reduce obesity-associated adipose inflammation."

Normally, the primary function of the is to transport lymph, a fluid containing infection-fighting white blood cells, throughout the body via lymphatic vessels. Lymphatic vessels are similar to the circulatory system's veins and capillaries. The lymphatic vasculature and lymphatic endothelial cells in tissues are essential for maintaining tissue balance through the uptake and transport of peripheral fluid, large molecules, and immune cells. Tissue inflammation is often accompanied by the formation of new lymph vessels, a process known as lymphangiogenesis. Although obesity seems to inhibit lymphangiogenesis and reduce lymphatic function in adipose tissue, the goal of this research was to determine whether artificially enhancing the lymph system in obese adipose tissue can be beneficial.

The investigators developed a new transgenic mouse model to test their hypothesis. The model allows for activation of receptor-3 (VEGFR-3), a receptor known to regulate lymphangiogenesis, by elevating expression of its ligand VEGF-D from fat cells. Unlike human VEGF-D, mouse VEGF-D does not affect blood vessel formation or function. The investigators used these inducible adipose VEGF-D overexpressing (Adipo-VD) mice fed a chronic high fat diet to identify the impact of increased VEGFR-3 signaling and lymphatic density in obese fat.

"We demonstrated that augmenting VEGF-D signaling specifically in induces lymphangiogenesis and improves glucose and lipid homeostasis during obesity," said Dr. Rutkowski.

"The studies showed that despite equivalent weight gain, the Adipo-VD mice demonstrate reduced systemic insulin resistance, liver lipid deposition, and adipose immune accumulation when compared to their littermates. For a long time, we did not think this model worked. Native lymphatics in mouse adipose are quite sparse. It turns out that our VEGF-D expression level was relatively low and lymphangiogenesis in this context takes months. It does align well with the four-month time course of diet-induced obesity that we used. We still have more mechanistic work to do, but the phenotype is exciting," concluded Dr. Rutkowski.

These findings highlight the importance of lymphatic expansion in maintaining homeostasis and identify a potential new target in the amelioration of the metabolic syndrome associated with .

More information: Adri Chakraborty et al, Vascular Endothelial Growth Factor–D (VEGF-D) Overexpression and Lymphatic Expansion in Murine Adipose Tissue Improves Metabolism in Obesity, The American Journal of Pathology (2019). DOI: 10.1016/j.ajpath.2018.12.008

Journal information: American Journal of Pathology

Provided by Elsevier